-+ 0.00%
-+ 0.00%
-+ 0.00%

Teva Expands Samsung Bioepis Collaboration With ETICOVO, Infliximab-Abda Deal; Upfront Payment Over 3 Years, Launch And Sales Milestones Possible, Profits Shared

Benzinga·11/03/2026 10:04:41
Listen to the news
  • Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027
  • Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s commercial capabilities
  • Agreement expands collaboration with Samsung Bioepis, strengthening Teva’s generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy